brolucizumab-dbll
Bevacizumab (Avastin) is the recommended formulary agent.
Reviewed: June 2024
Brolucizumab-dbll (Beovu)
Bevacizumab (Avastin) is the recommended formulary agent.
Reviewed: June 2024
Brolucizumab-dbll (Beovu)